The blockbusters KEYTRUDA and Gardasil were the main revenue items, their sales went up by 18% and 39% year-over-year, respectively. Moreover, the former is predicted to be the top-selling drug in terms of revenue - so far this position is occupied by Humira from AbbVie. KEYTRUDA is an anti-cancer drug that has already been approved for use together with, before and after chemotherapy for breast cancer. The tests of the drug were as successful as possible for the company, which ultimately gave it such a result. In May, the share price already surpassed the historical record of $92.2 from November 2000, reaching almost $95. After a slight correction, there is likely going to be a further upward movement to $100 . Without big turmoil in the stock market in a few days, Merck may first make new highs and then storm the round mark. A good support here is $90.5.